louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02597582: LigaSure Small Jaw® Versus Conventional Neck Dissection in Head and Neck Cancer Patients
Official title: A Prospective Randomized Study of LigaSure Small Jaw® Versus Conventional Neck Dissection in Head and Neck Cancer Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Head and Neck Neoplasms
Keywords: LigaSure
Neck dissection
Operative duration
Postoperative drainage
Postoperative pain
Lead sponsor: Taichung Veterans General Hospital
Sponsor class: OTHER
First posted: 2015-11-05
Enrollment: 41
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The aim of this prospective randomized study was to investigate if the LigaSure vessel sealing system can reduce the operation duration and the postoperative drainage amount in patients undergoing neck dissection.

Detailed description: We compared the differences in perioperative and postoperative variables between LigaSure Small Jaw®-assisted and conventional neck dissection in head and neck cancer patients.

Patients who were scheduled to undergo neck dissection due to head and neck cancer were eligible for this study. After receiving a detailed explanation, all patients signed an informed consent form before randomization. The study group were treated using the LigaSure vessel sealing system (Small Jaw®; Covidien, Colorado, USA) for dissection and hemostasis throughout the whole procedures during neck dissection. Relevant data included tumor-related variables, perioperative parameters, postoperative drainage status, postoperative subjective pain, and analgesic consumption amount were recorded and analyzed.

Eligibility criteria: Inclusion Criteria:

* Patients aged 20 to 80 years scheduled to receive neck dissection due to head and neck cancer

Exclusion Criteria:

* history of coagulation disorders
* prior radiation to the neck
* prior neck dissection
* declined to participate

Primary outcomes:
measure: Opreation Duration
timeFrame: 1 day
Secondary outcomes:
measure: Intraoperative Blood Loss
timeFrame: 1 day
measure: Postoperative Drainage Amount
timeFrame: 2 weeks
measure: Postoperative Subjective Pain Status
timeFrame: 2 weeks
measure: Postoperative Oral Analgesic Consumption
timeFrame: 2 weeks
measure: Postoperative Injected Analgesic Amount
timeFrame: 2 weeks
Other outcomes:
Locations:
city: Taichung
country: Taiwan
facility: Taichung Veterans General Hospital
Study officials:
affiliation: Taichung Veterans General Hospital
name: Shih-An Liu, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Lin WJ, Wang CC, Jiang RS, Huang YC, Ho HC, Liu SA. A prospective randomised trial of LigaSure Small Jaw(R) versus conventional neck dissection in head and neck cancer patients. Clin Otolaryngol. 2017 Apr;42(2):245-251. doi: 10.1111/coa.12702. Epub 2016 Jul 26.
Clinical trial NCT04171882: Microglial Cells Activation Imaging Using PET-CT With 18F-DPA714
Official title: In Vivo Assessment of Neuroinflammation With 18-FDPA714 PET/CT
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Microglial Cells Activation Imaging
Lead sponsor: First Affiliated Hospital of Fujian Medical University
Sponsor class: OTHER
First posted: 2019-11-21
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with neurological or psychiatry diseases or known brain lesion

Brief summary: There is accumulating evidence suggesting that inflammatory processes, through microglial activation, would play a key role in brain injury and degeneration. It is considered that microglial activation would be part of self-propelling cycle of neuroinflammation that fuels Neurologic deterioration. It is however hard to evidence microglial activation in vivo: first, the investigators need very high-resolution imaging tools and then, the only ligand available to date, 11C-PK11195, has a low sensitivity and specificity and provided heterogeneous results. 18F-DPA-714 is a new PET ligand which labels microglial cells. The investigators aim to explore the clinical feasibility used PET-CT with 18F-DPA714 to monitor microglial cells activation of brain in several different disease. This study might reveal significant neuroinflammatory process in the brain. The results of this study might provide a new biomarker of disease pathological progression and help as identifying subjects who might most benefit from a specific anti-inflammatory drug.


Eligibility criteria: Inclusion Criteria:

* Age \> 18 years
* Positron emission tomography scans were acquired more than twice
* Written informed consent was provided by the patients and their health care proxies -

Exclusion Criteria:

* Contraindication for PET examination

Primary outcomes:
measure: Standardized Uptake Value (SUV)
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Fuzhou
country: China
facility: Miu weibing
city: Tianjin
country: China
facility: Yao shaobo
Study officials:
References:
Clinical trial NCT02403882: Behavioral Economic Interventions at Food Pantries
Official title: An Analysis of Behavioral Economic Interventions at Client-Choice Food Pantries
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Food Selection
Keywords: behavioral economics
food pantry
food choice
Lead sponsor: Auburn University
Sponsor class: OTHER
Collaborators: name: Cornell University
First posted: 2015-03-31
Enrollment: 443
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators run a series of behavioral economic interventions at client-choice food pantries to encourage clients to choose targeted foods.

Detailed description: The study includes simple interventions at food pantries in New York State. In the initial phase, the investigators are testing the effect of order, packaging, pricing products, and relative proportion of products at a food pantry.

Eligibility criteria: Inclusion Criteria:

* Client in food pantry

Exclusion Criteria:

* Minors

Primary outcomes:
measure: Number of Targeted Products Selected Relative to Others
timeFrame: up to 8 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Auburn University
name: Norbert L Wilson, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Cornell University
name: David R. Just, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Wansink B, Just DR, Payne CR, Klinger MZ. Attractive names sustain increased vegetable intake in schools. Prev Med. 2012 Oct;55(4):330-332. doi: 10.1016/j.ypmed.2012.07.012. Epub 2012 Jul 27.
citation: Wansink B, Just DR, Payne CR. Can branding improve school lunches? Arch Pediatr Adolesc Med. 2012 Oct;166(10):1-2. doi: 10.1001/archpediatrics.2012.999. No abstract available.
citation: Hanks AS, Just DR, Wansink B. Smarter lunchrooms can address new school lunchroom guidelines and childhood obesity. J Pediatr. 2013 Apr;162(4):867-9. doi: 10.1016/j.jpeds.2012.12.031. Epub 2013 Feb 22.
citation: Wansink B, Just DR, Hanks AS, Smith LE. Pre-sliced fruit in school cafeterias: children's selection and intake. Am J Prev Med. 2013 May;44(5):477-80. doi: 10.1016/j.amepre.2013.02.003.
citation: Wilson NLW, Just DR, Swigert J, Wansink B. Food pantry selection solutions: a randomized controlled trial in client-choice food pantries to nudge clients to targeted foods. J Public Health (Oxf). 2017 Jun 1;39(2):366-372. doi: 10.1093/pubmed/fdw043.
Clinical trial NCT04668482: Sweat Gland Function in Patients With Failed Back Surgery Syndrome, Treated With Spinal Cord Stimulation
Official title: Sweat Gland Function in Patients With Failed Back Surgery Syndrome, Treated With Spinal Cord Stimulation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Failed Back Surgery Syndrome
Lead sponsor: Universitair Ziekenhuis Brussel
Sponsor class: OTHER
First posted: 2020-12-16
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: BASIC_SCIENCE

Brief summary: This study is investigating sweat gland function during on and off states of the spinal cord stimulator, in patients with failed back surgery syndrome.


Eligibility criteria: Inclusion Criteria:

* Subject is at least 18 years old.
* Diagnosis of FBSS (Failed conservative treatments for pain including but not limited to pharmacological therapy and physical therapy) and currently being treated with spinal cord stimulation.
* Cognitive and language functioning enabling coherent communication between the examiner and the participant.

Exclusion Criteria:

* Patients with major psychiatric problems.

Primary outcomes:
measure: Sweat gland function by measuring Electrochemical Skin Conductances (ESC)
timeFrame: The change between the measurement while SCS is switched off and while SCS is switched on. Total study duration lasts one day.
Secondary outcomes:
measure: Pain intensity scores using the Visual Analogue Scale
timeFrame: Two times on the same day; once while SCS is switched off and once while SCS is switched on. Total study duration lasts one day.
Other outcomes:
Locations:
city: Jette
country: Belgium
facility: Universitair Ziekenhuis Brussel
Study officials:
affiliation: Universitair Ziekenhuis Brussel
name: Maarten Moens, Prof. dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04457882: Evaluation of the Safety of Intraperitoneal Laparoscopic Radical Prostatectomy With or Without Drainage Tube
Official title: Evaluation of the Safety of Intraperitoneal Laparoscopic Radical Prostatectomy With or Without Drainage Tube: a Singlecentre, Randomised Controlled, and Non-inferiority Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Prostate Cancer
Keywords: Prostate Cancer
Laparoscopic Radical Prostatectomy
Intraperitoneal
Drainage Tube
Lead sponsor: Shanghai East Hospital
Sponsor class: OTHER
First posted: 2020-07-07
Enrollment: 112
Sex: MALE
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a randomized controlled and non-inferiority trial in comparison of intraperitoneal laparoscopic radical prostatectomy without drainage tube between intraperitoneal laparoscopic radical prostatectomy with drainage tube in the safety in men with a localized prostate cancer.

Detailed description: This trial is a prospective, single-centre, randomized controlled, and non-inferiority study in which all men with localized prostate cancer. This study aims to determine whether intraperitoneal laparoscopic radical prostatectomy without drainage tube is non-inferior to intraperitoneal laparoscopic radical prostatectomy with drainage tube in the safety in men with a localized prostate cancer.

Eligibility criteria: Inclusion Criteria:

1. age: more than 18 years old, less than 85 years old;
2. Patient who pathologically diagnosed with prostate cancer and plan to undergo radical laparoscopic surgery for prostate cancer;
3. fully understand the clinical trial protocol and sign the informed consent;

Exclusion Criteria:

1. patients with surgical contraindications who cannot accept surgery;
2. patients with non-laparoscopic radical resection of prostate cancer;
3. patients with previous pelvic radiation therapy and complicated abdominal surgery;
4. patients judged by the investigator to be unsuitable to participate in the clinical trial;

Primary outcomes:
measure: The rate of adverse event
timeFrame: 3 month
Secondary outcomes:
measure: Hemoglobin
timeFrame: 3 Months
measure: Physical recovery
timeFrame: 3 Months
measure: Intestinal function recovery
timeFrame: 3 Months
measure: Abdominal effusion and cyst
timeFrame: 3 Months
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai East Hospital, Tongji University School of Medicine
state: Shanghai
Study officials:
affiliation: Shanghai East Hospital,Tongji University School of Medicine
name: Haifeng Wang
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00748982: Investigate the Effect of AZD1305 on Patients With Left Ventricular Dysfunction
Official title: A Single-centre, Single-blind, Randomised, Placebo-controlled Phase IIa Study to Investigate the Effect of AZD1305 Given as an Intravenous (iv) Infusion on Left Ventricular Performance in Patients With Left Ventricular Dysfunction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Left Ventricle Function
Keywords: AZD1305
anti-arrhythmics
safety
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2008-09-09
Enrollment: 16
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To explore if AZD1305 compromises left ventricular performance in patients with left ventricular dysfunction


Eligibility criteria: Inclusion Criteria:

* Male patients and postmenopausal women
* Mildly/moderately decreased heart function
* Regular heart rhythm

Exclusion Criteria:

* Potassium outside normal reference values
* Child bearing potential
* Severely decreased heart function

Primary outcomes:
measure: Left Ventricular Ejection Fraction (LVEF), Change From Baseline
timeFrame: From the iv loading dose during 30 min and the following maintenance iv dose during a maximum of 90 min. The infusion was stopped when all echocardiographic measurements had been carried out
Secondary outcomes:
measure: Number of Subjects With at Least One Reported Adverse Event During Each Study Period and in Each Dose Group
timeFrame: From randomisation to last study visit (mean infusion time 1.6 hours)
measure: Area Under Curve (AUC) ( µmol*h/L) of AZD1305
timeFrame: From the iv loading dose during 30 min and the following maintenance iv dose during a maximum of 90 min.
measure: QTcF Interval
timeFrame: Up to 24 hours following start of IV dosing.
Other outcomes:
Locations:
city: Goteborg
country: Sweden
facility: Research Site
Study officials:
affiliation: AstraZeneca R&D, Mölndal, Sweden
name: Helen Lund, MD
role: STUDY_DIRECTOR
affiliation: AstraZeneca, Clinical Pharmacology Unit at Sahlgrenska University Hospital, Sweden
name: Marianne Hartford, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04128982: Vidéolaryngoscopy Study of the LPEC in Obese Patients
Official title: Evaluation of the Impact of Sellick's Manoeuvre or Para-tracheal Compression of the Cervical Esophagus on Laryngeal Mass Movement and Vocal Cord Visualization in Obese Patients.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Videolaryngoscopy
Lead sponsor: University of Liege
Sponsor class: OTHER
First posted: 2019-10-16
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults patients obese

Brief summary: 1. Check the intubation conditions during laryngoscopy without external mobilization of the larynx, with Sellick manoeuvre or with low paratracheal esophagal compression in obese patient
2. International surveys comparing tracheal intubation difficulty on a scale of 1 to 3 between cricoid pressure, Left Paratracheal Esophageal Compression and neutral position

Detailed description: Check the intubation conditions during laryngoscopy without external mobilization of the larynx, with Sellick manoeuvre or with low paratracheal esophagal compression in obese patient

International surveys comparing tracheal intubation difficulty on a scale of 1 to 3 between cricoid pressure, Left Paratracheal Esophageal Compression and neutral position

Eligibility criteria: Inclusion Criteria:

* Adults patients with BMI \> 35 undergoing general anaesthesia

Exclusion Criteria:

* pregnant women
* people with facial
* oropharyngeal abnormalities

Primary outcomes:
measure: Distance between oesophagus and trachea
timeFrame: During laryngoscopy
Secondary outcomes:
Other outcomes:
Locations:
city: Liège
country: Belgium
facility: Javillier
Study officials:
References:
Clinical trial NCT06927882: Effects of Whole Body Vibration Therapy on Cognitive Function, Balance, and Quality of Life in Older Adults With Mild Cognitive Impairment
Official title: Effects of Whole Body Vibration Therapy on Cognitive Function, Balance, and Quality of Life in Older Adults With Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Cognitive Impairment
Balance
Quality of Life
Lead sponsor: Jouf University
Sponsor class: OTHER
First posted: 2025-04-15
Enrollment: 180
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a double-blind, randomized controlled trial comparing WBV therapy with a placebo intervention and standard care. A total of 150 participants will be recruited and investigated from Prince Mutib Hospital. Participants will be randomly allocated to one of three groups: WBV therapy, placebo (non-vibrating platform), or control (standard care). The study duration will be 12 weeks, with assessments conducted at baseline, post-intervention (12 weeks), and at a 6-month follow-up.

Protocol Parameters Summary

* Session Frequency: 3 times per week.
* Session Duration: 25 minutes per session.
* Vibration Frequency: 30 Hz.
* Amplitude: 1-2 mm.
* Program Duration: 12 weeks.


Eligibility criteria: Inclusion Criteria:

* Adults aged 60 years and older.
* Diagnosed with mild cognitive impairment (Montreal Cognitive Assessment (MoCA) score of 18-25). One point is added if years of education are less than 12 years\[2\].
* Able to stand independently or with minimal assistance.
* No contraindications for WBV therapy or exercise.

Exclusion Criteria:

* Diagnosis of dementia.
* Severe musculoskeletal or neurological disorders.
* Implanted electronic medical devices (e.g., pacemaker).
* Inability to comprehend study instructions.

Primary outcomes:
measure: Montreal Cognitive Assessment (MoCA) for Cognitive Function
timeFrame: 6 months
Secondary outcomes:
measure: Berg Balance Scale
timeFrame: 6 months
measure: • Quality of Life
timeFrame: 12 weeks
measure: Timed up and go test
timeFrame: 6 month
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05311982: Transcranial Direct Current Stimulation in Autistic Spectrum Disorder
Official title: Transcranial Direct Current Stimulation Modulates Spectral Power and Coherence in Autism Spectrum Disorder: a Triple-blind, Placebo-controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Autistic Disorders Spectrum
Keywords: Autism
Tdcs
EEG
Lead sponsor: Federal University of Paraíba
Sponsor class: OTHER
First posted: 2022-04-05
Enrollment: 12
Sex: ALL
Minimum age (years): 5
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: To understand the changes in the resting electroencephalogram (EEG) brain networks of children and adolescents with autistic spectrum disorder (ASD) induced by transcranial direct current stimulation (tDCS), we asked two questions. First: how can tDCS modulate the expression of neural network dynamics? Second: how can tDCS modulate functional connections at specific frequencies? We hypothesized that the tDCS mechanism results in increased cortical frequencies in the areas under the anode, which may reflect an increase in synaptic connectivity, and that this tDCS-related increase changes connection profiles at specific frequencies important for ASD, indicating improvement in symptoms. To verify this improvement, the researchers used the Autism Treatment Evaluation Checklist (ATEC) after an intervention, comparing baseline scores with post-treatment scores.


Eligibility criteria: Inclusion Criteria:

Patients with ASD reported by a Neuropediatrician; Age group between 5 and 18 years; Mild and moderate clinical symptoms

Exclusion Criteria:

Patients with severe mental illness; Use of a pacemaker or other metal device on the body; Brain tumor or intracranial infection; Uncooperative parents or caregivers; Epilepsy; structural change in the skull

Primary outcomes:
measure: to compare the effectiveness of Neuromodulation techniques - transcranial direct current stimulation (tDCS) - in the treatment of people with Autism Spectrum Disorder
timeFrame: 7 weeks
Secondary outcomes:
measure: Check the effects of tDCS modulations on cognitive responses through Autism Treatment Evaluation Checklist
timeFrame: 7 weeks
Other outcomes:
Locations:
city: João Pessoa,
country: Brazil
facility: Federal University of Paraíba,Department of Psychology
state: Paraiba
city: João Pessoa
country: Brazil
facility: Suellen Marinho Andrade
state: Paraíba
Study officials:
References: